Diabetes & kardiometabolisch
13 StudienSUMMIT2025Tirzepatide for Heart Failure with Preserved Ejection Fraction and ObesitySURPASS-CVOT2025A Study of Tirzepatide Compared with Dulaglutide on Major Cardiovascular Events in Participants with Type 2 DiabetesSOUL2025A Heart Disease Study of Semaglutide in Patients with Type 2 Diabetes (Semaglutide cardiOvascular oUtcomes triaL)SURMOUNT-52025A Study of Tirzepatide Compared With Semaglutide in Participants With Obesity or OverweightFLOW2024Semaglutide and Kidney Outcomes in Type 2 Diabetes with Chronic Kidney DiseaseSELECT2023Semaglutide and Cardiovascular Outcomes in Obesity without DiabetesSTEP 12021Once-Weekly Semaglutide in Adults with Overweight or ObesityDAPA-CKD2020Dapagliflozin and Prevention of Adverse Outcomes in Chronic Kidney DiseaseDECLARE-TIMI 582019Dapagliflozin and Cardiovascular Outcomes in Type 2 DiabetesCREDENCE2019Canagliflozin and Renal Events in Diabetes with Established NephropathyLEADER2016Liraglutide Effect and Action in Diabetes: Evaluation of Cardiovascular Outcome ResultsSUSTAIN-62016Trial to Evaluate CV and Other Long-term Outcomes with SemaglutideEMPA-REG OUTCOME2015Empagliflozin Cardiovascular Outcome Event Trial in Type 2 Diabetes